Skip to main content
Vaxcell-Bio Therapeutics logo

Vaxcell-Bio Therapeutics — Investor Relations & Filings

Ticker · 323990 ISIN · KR7323990002 KO Manufacturing
Open in API
Filings indexed 228 across all filing types
Latest filing 2025-04-08 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 323990

About Vaxcell-Bio Therapeutics

https://vaxcell-bio.com/en/

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of innovative immunotherapies. The company's primary focus is on oncology, developing a pipeline of cell-based and protein-based treatments, including immune cell therapies and targeted protein-degrading therapeutics. In addition to its core focus on cancer, Vaxcell-Bio is expanding its research into other areas, such as developing drug delivery system (DDS)-based therapies for conditions like macular degeneration.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction filing ('정정신고'). It details the adjustment of the exercise price of stock options due to a merger. In the context of Korean regulatory filings (DART), this type of disclosure regarding stock option grants and their subsequent amendments falls under general regulatory announcements as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes). Therefore, it is classified as a Regulatory Filing (RNS).
2025-04-08 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction filing ('정정신고'). It details the adjustment of exercise prices for stock options due to a merger. While it relates to shares, it is specifically a disclosure of stock option grants and their subsequent price adjustments, which falls under general regulatory filings (RNS) as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2025-04-08 Korean
유형자산취득결정(자율공시)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from Vaxcell-Bio regarding the decision to acquire tangible assets (a building for R&D and manufacturing). It follows the standard format for a corporate disclosure of a material event (acquisition of assets). Since it does not fit into specific categories like M&A (which usually refers to corporate mergers/acquisitions of entities), dividends, or financial reports, it falls under the general regulatory filing category.
2025-04-02 Korean
[기재정정]합병등종료보고서(합병)
M&A Activity Classification · 1% confidence The document is a 'Report on the Completion of Merger' (합병등종료보고서) filed by Vaxcell-Bio. It details the finalization of a merger with AL Biotech, including the merger date, share issuance, and post-merger financial status. This document is a formal regulatory filing required by the Financial Supervisory Service (FSS) in South Korea to report the conclusion of a corporate merger transaction. It fits the 'M&A Activity' (TAR) category as it pertains to the finalization of a merger/takeover bid.
2025-03-28 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a company merger (회사합병 결정) between Vaxcell-Bio and AL Biotech. It details the merger ratio, valuation methods, external evaluation reports, and legal compliance under the Capital Markets Act. This type of filing is a standard regulatory disclosure for M&A activity in the Korean market, which falls under the 'M&A Activity' category.
2025-03-25 Korean
합병등종료보고서(합병)
M&A Activity Classification · 1% confidence The document is titled '합병등종료보고서' (Report on the Completion of Merger, etc.) filed by Vaxcell-Bio with the Financial Supervisory Service (FSS). It details the finalization of a merger process, including the merger date, share allocation, creditor protection procedures, and post-merger financial status. This is a formal regulatory filing documenting the conclusion of a corporate M&A transaction, which falls under the category of M&A Activity (TAR).
2025-03-25 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.